Metformin as a Chemo Add-On: 19 Trials Pooled — No Survival Gain, but More Tumors Shrank
Across 19 randomized trials (3,502 patients), adding metformin to chemotherapy did not improve progression-free or overall survival (HR 1.08 both), but raised response rates (OR 1.59) without extra severe toxicity.
By Sanare Lab · October 11, 2026 · 2 min read
Key Takeaway
Adding metformin to chemotherapy did not help patients live longer or stay progression-free in a meta-analysis (a pooled analysis) of 19 randomized trials with 3,502 people. Tumors did shrink a bit more often, with no extra severe side effects. Survival hints in subgroups are exploratory — not proven.
Researchers pooled 19 randomized controlled trials — the gold standard, where patients are randomly assigned to a treatment or control group — testing the diabetes drug metformin alongside chemotherapy. On the primary endpoints (the outcomes the analysis was built around): progression-free survival, the time without the cancer growing, was unchanged (hazard ratio HR 1.08 — HR 1 means no difference), and overall survival was unchanged too (HR 1.08).
The one positive: overall response rate — the share of patients whose tumors shrink — improved (odds ratio OR 1.59, 95% CI 1.02–2.46; CI is the uncertainty range), driven by complete responses, meaning tumors disappearing on scans. Exploratory subgroup looks (secondary slicing, not the main test) hint at a survival benefit at 1,500 mg/day with platinum chemo (HR 0.61) — hypothesis-generating only. Severe grade ≥3 side effects (the most serious category) were no more common with metformin (OR 1.10).
Bottom line: metformin is safe to combine but is no survival booster overall; the subgroup signal needs its own prospective trials. See our earlier metformin meta-analysis and metformin and chemo resistance research; dosing: our dosing calculator.
In plain words
What happened: Researchers pooled 19 randomized trials (3,502 people) that added the diabetes drug metformin to standard chemotherapy.
Why it matters: Metformin is cheap and widely tolerated, and lab studies hint it could boost chemo — this analysis asked whether that holds in real randomized trials.
How strong is the evidence: A strong design, and the honest answer is mixed: no survival benefit overall; tumors shrank somewhat more often; survival signals in subgroups are exploratory.
What it means for you: If you are on chemo, this changes nothing — do not start metformin on your own; it must fit your treatment plan. Discuss any add-on with your oncology team.
References
- Bin Saddiq BW, Morad AS, Khan TN, et al. Revisiting metformin as a chemotherapy adjuvant (add-on): a systematic review and meta-analysis of recent randomized trials. Frontiers in Oncology. 2026 Sep 9. doi:10.3389/fonc.2026.1888506. PMID: 42840671.
- Correction: Frontiers in Oncology. 2026. doi:10.3389/fonc.2026.2000444. PMID: 42840417.
Medical Disclaimer
This article is for informational purposes only and is not medical advice. Never start, stop or change any medication or supplement without consulting your doctor.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.